Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Stimulant Use Disorder: early-phase trial registry

7 of 10 indexed Stimulant Use Disorder trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 7 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Stimulant Use Disorder: 10 US clinical trials tracked, 7 recruiting.

Stimulant Use Disorder is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is University of Minnesota, running 2 of these trials.

Enrollment posture brief

Registry condition stimulant-use-disorder

OPEN 7 | RECR 70% | LATE 0 | EARLY 5 | RANK #1724 | SPON 2

Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)

Acute Leukemia of Ambiguous 80%Stimulant Use Disorder (this)70%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Stimulant Use Disorder

Stimulant Use Disorder lists 7 open slots (70% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stimulant Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stimulant Use Disorder is recruiting above its size-band peers.

    7 of 10 indexed trials (70%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stimulant Use Disorder research.

    University of Minnesota accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Stimulant Use Disorder trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.

  4. Stimulant Use Disorder research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22

Open and recent trials

10 total, page 1 of 1

RECRUITING NA 500 participants

reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)

University of Miami

NCT05958017

RECRUITING NA 304 participants

Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use

Elana Rosenthal

NCT06513156

RECRUITING NA 270 participants

Smartphone Services for Stimulant Use Disorder

DynamiCare Health

NCT07092059

RECRUITING Phase 2 60 participants

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

Washington State University

NCT06323837

RECRUITING Phase 1 50 participants

Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder

University of Minnesota

NCT06790576

RECRUITING Early Phase 1 24 participants

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

William Stoops

NCT05610072

RECRUITING Phase 2 20 participants

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

The University of Texas Health Science Center, Houston

NCT06444256

ACTIVE NOT RECRUITING NA 600 participants

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

Yale University

NCT05286879

ACTIVE NOT RECRUITING NA 56 participants

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

University of Minnesota

NCT05288751

ACTIVE NOT RECRUITING Phase 1 12 participants

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

University of Wisconsin, Madison

NCT05322954

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2

Named interventions

Most-linked intervention names on Stimulant Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Mobile Health Unit Behavioral
1 trials
Patient Navigator Behavioral
1 trials
Placebo hydromorphone Drug
1 trials
Placebo n-acetylcystine Drug
1 trials
n-acetylcysteine Drug
1 trials
Mirtazapine Drug
1 trials
closed-loop-trough Other
1 trials
Open-loop Other
1 trials

US sites by state

Facility locations filed on Stimulant Use Disorder trials. A trial with sites in several states counts in each.

Texas 2 trials
Minnesota 2 trials
West Virginia 1 trials
Wisconsin 1 trials
Washington 1 trials
Maryland 1 trials
Massachusetts 1 trials
Kentucky 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stimulant Use Disorder page

10 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stimulant Use Disorder condition card totals 10 registered trials; most-linked intervention Mobile Health Unit; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.